Literature DB >> 28160947

The "Scope" of Post-ERCP Pancreatitis.

Parth J Parekh1, Raj Majithia2, Sanjay K Sikka1, Todd H Baron3.   

Abstract

Pancreatitis is the most common adverse event of endoscopic retrograde cholangiopancreatography, with the potential for clinically significant morbidity and mortality. Several patient and procedural risk factors have been identified that increase the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). Considerable research efforts have identified several pharmacologic and procedural interventions that can drastically affect the incidence of PEP. This review article addresses the underlying mechanisms at play for the development of PEP, identifying patient and procedural risk factors and meaningful use of risk-stratification information, and details current interventions aimed at reducing the risk of this complication.
Copyright © 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28160947     DOI: 10.1016/j.mayocp.2016.10.028

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  8 in total

1.  Serum lipase as a biomarker for early prediction and diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Yu Zhang; Xiaoling Ye; Xinyue Wan; Tao Deng
Journal:  Ir J Med Sci       Date:  2019-08-28       Impact factor: 1.568

Review 2.  Endoscopic Retrograde Cholangiopancreatography-Related Complications and Their Management Strategies: A "Scoping" Literature Review.

Authors:  Kemmian D Johnson; Abhilash Perisetti; Benjamin Tharian; Ragesh Thandassery; Priya Jamidar; Hemant Goyal; Sumant Inamdar
Journal:  Dig Dis Sci       Date:  2019-12-02       Impact factor: 3.199

3.  Effectiveness of supraglottic ventilation by transtracheal catheter for painless ERCP.

Authors:  Shaojin Zhang; Jiying Nie; Wencai Tu; Changgen Zhong; Qing Liu; Jianhua Li
Journal:  Am J Transl Res       Date:  2021-07-15       Impact factor: 3.940

4.  Development and validation of a risk prediction model and scoring system for post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Ruhua Zheng; Mengjie Chen; Xuying Wang; Bingqiang Li; Ting He; Lei Wang; Guifang Xu; Yuling Yao; Jun Cao; Yonghua Shen; Yi Wang; Hao Zhu; Bin Zhang; Han Wu; Xiaoping Zou; Guoping He
Journal:  Ann Transl Med       Date:  2020-10

5.  The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice.

Authors:  Dannielle D Engle; Hervé Tiriac; Keith D Rivera; Arnaud Pommier; Sean Whalen; Tobiloba E Oni; Brinda Alagesan; Eun Jung Lee; Melissa A Yao; Matthew S Lucito; Benjamin Spielman; Brandon Da Silva; Christina Schoepfer; Kevin Wright; Brianna Creighton; Lauren Afinowicz; Kenneth H Yu; Robert Grützmann; Daniela Aust; Phyllis A Gimotty; Katherine S Pollard; Ralph H Hruban; Michael G Goggins; Christian Pilarsky; Youngkyu Park; Darryl J Pappin; Michael A Hollingsworth; David A Tuveson
Journal:  Science       Date:  2019-06-21       Impact factor: 63.714

6.  Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment.

Authors:  Murat Pekgöz
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

7.  Serum microRNAs as Biomarkers for the Noninvasive Early Diagnosis of Biliary Tract Cancer.

Authors:  Yueting Han; Haiyang Zhang; Zhengyang Zhou; Rui Liu; Dongying Liu; Ming Bai; Qian Fan; Jialu Li; Kegan Zhu; Hongli Li; Tao Ning; Guoguang Ying; Yi Ba
Journal:  Int J Gen Med       Date:  2021-04-01

8.  Activin A Modulates Inflammation in Acute Pancreatitis and Strongly Predicts Severe Disease Independent of Body Mass Index.

Authors:  Alexandra L Thomas; Karla Castellanos; Georgina Mancinelli; Yinglin Xia; Jessica Bauer; Cemal Yazici; Giamila Fantuzzi; Rosa F Hwang; Nancy L Krett; Georgios I Papachristou; David C Whitcomb; Barbara Jung
Journal:  Clin Transl Gastroenterol       Date:  2020-05       Impact factor: 4.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.